The company did not provide specific guidance or forecasts for the current or future periods in its press release.
Overview
U.S. eye care pharma's Q2 2026 revenue reached $5.5 million, driven by VIZZ sales and licenses.
The company posted a Q2 net loss of $31.9 million amid higher launch and marketing expenses.
VIZZ product sales rose 9% over Q1 2026; telehealth and TV campaigns launched in July.
Result drivers
Patient refills - Over 60% of ePharmacy patients purchased multiple monthly packs since launch, with early cohorts tracking to five packs annually, per CEO Eef Schimmelpennink.
License revenue - Q2 license revenue included milestone and sublicense payments from international commercialization agreements.
Analyst coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is , and no or .
LENZ•
